Squarepoint’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-17,762
| Closed | -$302K | – | 5017 |
|
|
2026
Q2 | $302K | Buy |
+17,762
| New | +$294K | ﹤0.01% | 3800 |
|
|
2026
Q1 | – | Sell |
-67,355
| Closed | -$1.26M | – | 4953 |
|
|
2025
Q4 | $1.26M | Buy |
67,355
+20,605
| +44% | +$342K | ﹤0.01% | 2410 |
|
|
2025
Q3 | $683K | Buy |
46,750
+33,428
| +251% | +$422K | ﹤0.01% | 2970 |
|
|
2025
Q2 | $147K | Sell |
13,322
-10,445
| -44% | -$102K | ﹤0.01% | 4068 |
|
|
2025
Q1 | $212K | Sell |
23,767
-23,401
| -50% | -$218K | ﹤0.01% | 3977 |
|
|
2024
Q4 | $444K | Sell |
47,168
-51,783
| -52% | -$471K | ﹤0.01% | 3826 |
|
|
2024
Q3 | $798K | Sell |
98,951
-17,305
| -15% | -$150K | ﹤0.01% | 2776 |
|
|
2024
Q2 | $986K | Buy |
+116,256
| New | +$1.05M | ﹤0.01% | 2567 |
|
|
2024
Q1 | – | Sell |
-52,054
| Closed | -$585K | – | 4598 |
|
|
2023
Q4 | $585K | Buy |
+52,054
| New | +$524K | ﹤0.01% | 2890 |
|
|
2023
Q3 | – | Sell |
-48,706
| Closed | -$504K | – | 4232 |
|
|
2023
Q2 | $504K | Sell |
48,706
-1,070
| -2% | -$11.8K | ﹤0.01% | 2616 |
|
|
2023
Q1 | $540K | Sell |
49,776
-18,503
| -27% | -$196K | ﹤0.01% | 2256 |
|
|
2022
Q4 | $766K | Buy |
68,279
+13,553
| +25% | +$142K | ﹤0.01% | 2015 |
|
|
2022
Q3 | $555K | Buy |
54,726
+35,741
| +188% | +$335K | ﹤0.01% | 2154 |
|
|
2022
Q2 | $172K | Buy |
+18,985
| New | +$175K | ﹤0.01% | 2519 |
|
|
2022
Q1 | – | Sell |
-15,971
| Closed | -$176K | – | 3503 |
|
|
2021
Q4 | $176K | Sell |
15,971
-19,255
| -55% | -$168K | ﹤0.01% | 2757 |
|
|
2021
Q3 | $261K | Buy |
+35,226
| New | +$394K | ﹤0.01% | 2329 |
|
|
2020
Q4 | – | Sell |
-49,919
| Closed | -$738K | – | 3254 |
|
|
2020
Q3 | $738K | Buy |
49,919
+38,069
| +321% | +$713K | 0.01% | 1168 |
|
|
2020
Q2 | $249K | Buy |
+11,850
| New | +$304K | ﹤0.01% | 1713 |
|
|
2019
Q4 | – | Sell |
-49,622
| Closed | -$967K | – | 2790 |
|
|
2019
Q3 | $967K | Sell |
49,622
-6,439
| -11% | -$130K | 0.01% | 1263 |
|
|
2019
Q2 | $915K | Buy |
56,061
+38,656
| +222% | +$783K | 0.01% | 1315 |
|
|
2019
Q1 | $395K | Buy |
+17,405
| New | +$441K | ﹤0.01% | 1612 |
|
|
2016
Q3 | – | Sell |
-12,300
| Closed | -$279K | – | 1248 |
|
|
2016
Q2 | $279K | Buy |
+12,300
| New | +$266K | 0.02% | 772 |
|
Other funds holding TBPH
Squarepoint's TBPH Position: Q3 2026 in Review
Squarepoint sold out of Theravance Biopharma (TBPH) in Q3 2026, closing a stake of 17,762 shares — an estimated $302K sold.
Squarepoint first reported a position in TBPH in Q2 2016 and held it in 22 quarters. The position peaked at $1.26M in Q4 2025. 3 funds tracked by Wall St. Rank hold TBPH as of Q3 2026.
- Squarepoint reported no remaining Theravance Biopharma position as of Q3 2026 after selling out during the quarter.
- Squarepoint sold 17,762 Theravance Biopharma shares in Q3 2026, an estimated $302K.
- Squarepoint first reported a position in Theravance Biopharma in Q2 2016 and held it in 22 quarters.
- Squarepoint's Theravance Biopharma position peaked at $1.26M in Q4 2025.
- 3 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2026.
Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.